{"id":4888,"date":"2019-05-17T17:12:04","date_gmt":"2019-05-17T17:12:04","guid":{"rendered":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/chapter\/part-vi-blood-typing\/"},"modified":"2019-09-25T09:23:53","modified_gmt":"2019-09-25T09:23:53","slug":"blood-typing-and-blood-transfusion","status":"publish","type":"chapter","link":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/chapter\/blood-typing-and-blood-transfusion\/","title":{"raw":"Blood Typing and Blood Transfusion","rendered":"Blood Typing and Blood Transfusion"},"content":{"raw":"<section id=\"main-content\" class=\"main-content\">\r\n<div class=\"media-body\">\r\n<div id=\"content\">\r\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\">\r\n<p id=\"fs-id2316252\">Blood transfusions in humans were risky procedures until the discovery of the major human blood groups by Karl Landsteiner, an Austrian biologist and physician, in 1900. Until that point, physicians did not understand that death sometimes followed blood transfusions, when the type of donor blood infused into the patient was incompatible with the patient\u2019s own blood. Blood groups are determined by the presence or absence of specific marker molecules on the plasma membranes of erythrocytes. With their discovery, it became possible for the first time to match patient-donor blood types and prevent transfusion reactions and deaths.<\/p>\r\n\r\n<section id=\"fs-id2382783\">\r\n<h2>Antigens, Antibodies, and Transfusion Reactions<\/h2>\r\n<p id=\"fs-id2715080\">Antigens are substances that the body does not recognize as belonging to the \u201cself\u201d and that therefore trigger a defensive response from the leukocytes of the immune system. (Seek more content for additional information on immunity.) Here, we will focus on the role of immunity in blood transfusion reactions. With RBCs in particular, you may see the antigens referred to as isoantigens or agglutinogens (surface antigens) and the antibodies referred to as isoantibodies or agglutinins. In this chapter, we will use the more common terms <strong>antigens and antibodies.<\/strong><\/p>\r\n<p id=\"fs-id1952985\"><strong>Antigens<\/strong> are generally large proteins, but may include other classes of organic molecules, including carbohydrates, lipids, and nucleic acids seen on RBCs. Following an infusion of incompatible blood, erythrocytes with foreign antigens appear in the bloodstream and trigger an immune response. Proteins called antibodies (immunoglobulins), which are produced by certain B lymphocytes called plasma cells, attach to the antigens on the plasma membranes of the infused erythrocytes and cause them to adhere to one another.<\/p>\r\n\r\n<ul id=\"fs-id2396137\">\r\n \t<li>Because the arms of the Y-shaped antibodies attach randomly to more than one nonself erythrocyte surface, they form clumps of erythrocytes. This process is called\u00a0<span id=\"term2080\">agglutination<\/span>.<\/li>\r\n \t<li>The clumps of erythrocytes block small blood vessels throughout the body, depriving tissues of oxygen and nutrients.<\/li>\r\n \t<li>As the erythrocyte clumps are degraded, in a process called\u00a0<strong><span id=\"term2081\">hemolysis<\/span><\/strong>, their hemoglobin is released into the bloodstream. This hemoglobin travels to the kidneys, which are responsible for filtration of the blood. However, the load of hemoglobin released can easily overwhelm the kidney\u2019s capacity to clear it, and the patient can quickly develop kidney failure.<\/li>\r\n<\/ul>\r\n<p id=\"fs-id2653848\">More than 50 antigens have been identified on erythrocyte membranes, but the most significant in terms of their potential harm to patients are classified in <strong>two groups: the ABO blood group and the Rh blood group.<\/strong><\/p>\r\n\r\n<\/section><section id=\"fs-id2111265\">\r\n<h3>1. The ABO Blood Group<\/h3>\r\n<p id=\"fs-id2454712\">Although the\u00a0<span id=\"term2082\">ABO blood group<\/span>\u00a0name consists of three letters, ABO blood typing designates the presence or absence of just two antigens, A and B. Both are glycoproteins. People whose erythrocytes have A antigens on their erythrocyte membrane surfaces are designated blood type A, and those whose erythrocytes have B antigens are blood type B. People can also have both A and B antigens on their erythrocytes, in which case they are blood type AB. People with neither A nor B antigens are designated blood type O. ABO blood types are genetically determined.<\/p>\r\n\r\n<\/section>\r\n<div class=\"os-figure\">\r\n<figure id=\"fig-ch19_06_03\">\r\n\r\n[caption id=\"\" align=\"alignleft\" width=\"607\"]<img id=\"74906\" class=\"\" src=\"https:\/\/cnx.org\/resources\/a9fa9181b953f0a6a9596420b0f714ad4a497b16\" alt=\"This table shows the different blood types, the antibodies in plasma, the antigens in the red blood cell, and the blood compatible blood types in an emergency.\" width=\"607\" height=\"466\" \/> <strong>Table\u00a0 1:\u00a0<\/strong>ABO Blood Group\u00a0This chart summarizes the characteristics of the blood types in the ABO blood group. See the text for more on the concept of a universal donor or recipient.[\/caption]<\/figure>\r\n<\/div>\r\n<section id=\"fs-id2111265\">Normally the body must be exposed to a foreign antigen before an antibody can be produced. This is not the case for the ABO blood group. Individuals with type A blood\u2014without any prior exposure to incompatible blood\u2014have preformed antibodies to the B antigen circulating in their blood plasma. These antibodies, referred to as anti-B antibodies, will cause agglutination and hemolysis if they ever encounter erythrocytes with B antigens. Similarly, an individual with type B blood has pre-formed anti-A antibodies. Individuals with type AB blood, which has both antigens, do not have preformed antibodies to either of these. People with type O blood lack antigens A and B on their erythrocytes, but both anti-A and anti-B antibodies circulate in their blood plasma.<\/section><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/section><section id=\"main-content\" class=\"main-content\">\r\n<div class=\"media-body\">\r\n<div id=\"content\">\r\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\"><section id=\"fs-id2344330\">\r\n<h2>2. Rh Blood Groups - Rhesus Factor<\/h2>\r\n<p id=\"fs-id2492889\">The\u00a0<span id=\"term2083\">Rh blood group<\/span>\u00a0is classified according to the presence or absence of a second erythrocyte antigen identified as Rh. (It was first discovered in a type of primate known as a <em><strong><span style=\"text-decoration: underline\">rhesus<\/span> <span style=\"text-decoration: underline\">macaque<\/span><\/strong><\/em>, which is often used in research, because its blood is similar to that of humans.) Although dozens of Rh antigens have been identified, only one, designated D, is clinically important. Those who have the Rh D antigen present on their erythrocytes\u2014about 85 percent of Americans\u2014are described as <strong>Rh positive (Rh<sup>+<\/sup>)<\/strong> and those who lack it are <strong>Rh negative (Rh<sup>\u2212<\/sup>).<\/strong> Note that the Rh group is distinct from the ABO group, so any individual, no matter their ABO blood type, may have or lack this Rh antigen. When identifying a patient\u2019s blood type, the Rh group is designated by adding the word positive or negative to the ABO type. For example, A positive (A<sup>+<\/sup>) means ABO group A blood with the Rh antigen present, and AB negative (AB<sup>\u2212<\/sup>) means ABO group AB blood without the Rh antigen.<\/p>\r\nBesides being a consideration for blood transfusion, parents who differ based on Rh status must be cautious to ensure that maternal antibodies do not destroy their child\u2019s red blood cells during fetal development, which can cause hemolytic anemia.\r\n<p style=\"text-align: center\"><strong><a class=\"autogenerated-content\" href=\"https:\/\/cnx.org\/contents\/FPtK1zmh@15.1:naelGNoN@9\/18-6-Blood-Typing#tbl-ch19_02\">Table\u00a0<\/a>summarizes the distribution of the ABO and Rh blood types within the United States.<\/strong><\/p>\r\n\r\n<div class=\"os-table\">\r\n<table id=\"tbl-ch19_02\" summary=\"Table 18.2 \">\r\n<thead>\r\n<tr>\r\n<th colspan=\"5\" scope=\"col\">Summary of ABO and Rh Blood Types within the United States<\/th>\r\n<\/tr>\r\n<tr>\r\n<th scope=\"col\">Blood Type<\/th>\r\n<th scope=\"col\">African-Americans<\/th>\r\n<th scope=\"col\">Asian-Americans<\/th>\r\n<th scope=\"col\">Caucasian-Americans<\/th>\r\n<th scope=\"col\">Latino\/Latina-Americans<\/th>\r\n<\/tr>\r\n<\/thead>\r\n<tbody>\r\n<tr>\r\n<td>A<sup>+<\/sup><\/td>\r\n<td>24<\/td>\r\n<td>27<\/td>\r\n<td>33<\/td>\r\n<td>29<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>A<sup>\u2212<\/sup><\/td>\r\n<td>2<\/td>\r\n<td>0.5<\/td>\r\n<td>7<\/td>\r\n<td>2<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>B<sup>+<\/sup><\/td>\r\n<td>18<\/td>\r\n<td>25<\/td>\r\n<td>9<\/td>\r\n<td>9<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>B<sup>\u2212<\/sup><\/td>\r\n<td>1<\/td>\r\n<td>0.4<\/td>\r\n<td>2<\/td>\r\n<td>1<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>AB<sup>+<\/sup><\/td>\r\n<td>4<\/td>\r\n<td>7<\/td>\r\n<td>3<\/td>\r\n<td>2<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>AB<sup>\u2212<\/sup><\/td>\r\n<td>0.3<\/td>\r\n<td>0.1<\/td>\r\n<td>1<\/td>\r\n<td>0.2<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>O<sup>+<\/sup><\/td>\r\n<td>47<\/td>\r\n<td>39<\/td>\r\n<td>37<\/td>\r\n<td>53<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>O<sup>\u2212<\/sup><\/td>\r\n<td>4<\/td>\r\n<td>1<\/td>\r\n<td>8<\/td>\r\n<td>4<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/div>\r\n<\/section><section id=\"fs-id2801178\">\r\n<h2>Determining ABO Blood Types<\/h2>\r\n<p id=\"fs-id2696923\">Clinicians are able to determine a patient\u2019s blood type quickly and easily using commercially prepared antibodies. An unknown blood sample is allocated into separate wells. Into one well a small amount of anti-A antibody is added, and to another a small amount of anti-B antibody. If the antigen is present, the antibodies will cause visible agglutination of the cells. The blood should also be tested for Rh antibodies.<\/p>\r\n\r\n<div class=\"os-figure\">\r\n<figure id=\"fig-ch19_06_02\">\r\n\r\n[caption id=\"\" align=\"alignleft\" width=\"517\"]<img id=\"65452\" src=\"https:\/\/cnx.org\/resources\/387433ee24cad9d0a576c5bd5944c5a726901211\" alt=\"This figure shows three different red blood cells with different blood types.\" width=\"517\" height=\"210\" \/> <strong>Figure 1:\u00a0<\/strong> Blood group testing.[\/caption]<\/figure>\r\n<div class=\"os-caption-container\"><strong><span id=\"4426\" class=\"os-title\">Cross Matching Blood Types :<\/span><\/strong><\/div>\r\n<div class=\"os-caption-container\"><span class=\"os-caption\">This sample of a commercially produced \u201cbedside\u201d card enables quick typing of both a recipient\u2019s and donor\u2019s blood before transfusion. The card contains three reaction sites or wells. One is coated with an anti-A antibody, one with an anti-B antibody, and one with an anti-D antibody (tests for the presence of Rh factor D). Mixing a drop of blood and saline into each well enables the blood to interact with a preparation of type-specific antibodies, also called anti-seras. Agglutination of RBCs in a given site indicates a positive identification of the blood antigens, in this case A and Rh antigens for blood type A<sup>+<\/sup>. For the purpose of transfusion, the donor\u2019s and recipient\u2019s blood types must match.<\/span><\/div>\r\n<div><\/div>\r\n<div class=\"os-caption-container\"><span style=\"color: #077fab;font-size: 1.15em;font-weight: 600;text-align: initial\">ABO Transfusion Protocols<\/span><\/div>\r\n<div><\/div>\r\n<div class=\"os-caption-container\"><span style=\"font-size: 1rem;text-align: initial\">To avoid transfusion reactions, it is best to transfuse only matching blood types; that is, a type B<\/span><sup style=\"text-align: initial\">+<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0recipient should ideally receive blood only from a type B<\/span><sup style=\"text-align: initial\">+<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0donor and so on. That said, in emergency situations, when acute hemorrhage threatens the patient\u2019s life, there may not be time for cross matching to identify blood type. In these cases, blood from a\u00a0<\/span><strong><span id=\"term2085\" style=\"font-size: 1rem;text-align: initial\">universal donor<\/span><span style=\"font-size: 1rem;text-align: initial\">\u2014an individual with type O<\/span><sup style=\"text-align: initial\">\u2212<\/sup><\/strong><span style=\"font-size: 1rem;text-align: initial\"><strong>\u00a0blood<\/strong>\u2014may be transfused. Recall that type O erythrocytes do not display A or B antigens. Thus, anti-A or anti-B antibodies that might be circulating in the patient\u2019s blood plasma will not encounter any erythrocyte surface antigens on the donated blood and therefore will not be provoked into a response. One problem with this designation of universal donor is if the O<\/span><sup style=\"text-align: initial\">\u2212<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0individual had prior exposure to Rh antigen, Rh antibodies may be present in the donated blood. Also, introducing type O blood into an individual with type A, B, or AB blood will nevertheless introduce antibodies against both A and B antigens, as these are always circulating in the type O blood plasma. This may cause problems for the recipient, but because the volume of blood transfused is much lower than the volume of the patient\u2019s own blood, the adverse effects of the relatively few infused plasma antibodies are typically limited. Rh factor also plays a role. If Rh<\/span><sup style=\"text-align: initial\">\u2212<\/sup><span style=\"font-size: 1rem;text-align: initial\">individuals receiving blood have had prior exposure to Rh antigen, antibodies for this antigen may be present in the blood and trigger agglutination to some degree. Although it is always preferable to cross match a patient\u2019s blood before transfusing, in a true life-threatening emergency situation, this is not always possible, and these procedures may be implemented.<\/span><\/div>\r\n<\/div>\r\n<\/section><\/div>\r\n<\/div>\r\n<div id=\"content\">\r\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\"><section id=\"fs-id1921655\">\r\n\r\n[caption id=\"attachment_2727\" align=\"alignleft\" width=\"467\"]<a href=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/2868\/2019\/04\/30115504\/blood-Compatiblity-Capture.png\"><img class=\"wp-image-2727 \" src=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/2868\/2019\/04\/30115504\/blood-Compatiblity-Capture.png\" alt=\"\" width=\"467\" height=\"453\" \/><\/a> <strong>Figure 2<\/strong>: Blood transfusion[\/caption]\r\n<p id=\"fs-id2449664\">A patient with <strong>blood type AB<sup>+<\/sup>\u00a0is known as the\u00a0<span id=\"term2086\">universal recipient<\/span>.<\/strong> This patient can theoretically receive any type of blood, because the patient\u2019s own blood\u2014having both A and B antigens on the erythrocyte surface\u2014does not produce anti-A or anti-B antibodies. In addition, an Rh<sup>+<\/sup>\u00a0patient can receive both Rh<sup>+<\/sup>\u00a0and Rh<sup>\u2212<\/sup>\u00a0blood. However, keep in mind that the donor\u2019s blood will contain circulating antibodies, again with possible negative implications.<\/p>\r\n<p id=\"fs-id2585008\">At the scene of multiple-vehicle accidents, military engagements, and natural or human-caused disasters, many victims may suffer simultaneously from acute hemorrhage, yet type O blood may not be immediately available. In these circumstances, medics may at least try to replace some of the volume of blood that has been lost. This is done by intravenous administration of a saline solution that provides fluids and electrolytes in proportions equivalent to those of normal blood plasma. Research is ongoing to develop a safe and effective artificial blood that would carry out the oxygen-carrying function of blood without the RBCs, enabling transfusions in the field without concern for incompatibility. These blood substitutes normally contain hemoglobin- as well as perfluorocarbon-based oxygen carriers.<\/p>\r\n\r\n<\/section><section id=\"fs-id1921655\"><footer class=\"footer\">\r\n<div>\r\n<div class=\"page-footer\">\r\n<h2><\/h2>\r\n<h2>The Cross-Matching Process<\/h2>\r\nMuch of the routine work of a blood bank involves testing blood from both donors and recipients to ensure that every recipient is given blood that is compatible and is as safe as possible. Several laboratory tests allow cross-matching of compatible blood between donor and recipient. Patients should ideally receive their own blood or type-specific blood products to minimize the chance of a transfusion reaction. Risks can be further reduced by cross-matching blood, but this process isn\u2019t always performed if time is short and the need for transfusion has not been anticipated.\r\n\r\nCross-matching involves mixing a sample of the recipient\u2019s serum with a sample of the donor\u2019s red blood cells and checking if the mixture agglutinates, or forms clumps. These clumps are the result of antibodies binding the red blood cells together. If agglutination is not obvious by direct vision, blood bank technicians check for agglutination with a microscope. If agglutination occurs, that particular donor\u2019s blood cannot be transfused to that particular recipient.\r\n\r\n<span style=\"color: #077fab;font-size: 1.15em;font-weight: 600\">Potential Transfusion Complications<\/span>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/footer>If a patient receives blood during a transfusion that is not compatible with his or her blood type, severe problems can occur. Acute hemolytic transfusion reactions occur if donated blood cells are attacked by matching host antibodies. This can cause shock-like symptoms, such as fever, hypotension, and disseminated intravascular coagulation from immune system mediated endothelial damage. Transfusion reactions are also associated with acute renal failure. Lung injury is common as well, due to pulmonary edema from fluid overload if plasma volume becomes too high or neutrophil activation during a transfusion reaction. If the donated blood is contaminated with bacteria, it may induce septic shock in the patient.\r\n\r\n<\/section>\r\n<h2 class=\"os-caption-container\"><strong><span id=\"term2084\">Hemolytic disease of the newborn (HDN)<\/span>\u00a0or erythroblastosis fetalis:<\/strong><\/h2>\r\n<section id=\"fs-id2344330\">\r\n<p id=\"fs-id1899114\">In contrast to the ABO group antibodies, which are preformed, antibodies to the Rh antigen are produced only in Rh<sup>\u2212<\/sup>\u00a0individuals after exposure to the antigen. This process, called sensitization, occurs following a transfusion with Rh-incompatible blood or, more commonly, with the birth of an Rh<sup>+<\/sup>\u00a0baby to an Rh<sup>\u2212<\/sup>\u00a0mother. Problems are rare in a first pregnancy, since the baby\u2019s Rh<sup>+<\/sup>\u00a0cells rarely cross the placenta (the organ of gas and nutrient exchange between the baby and the mother). However, during or immediately after birth, the Rh<sup>\u2212<\/sup>\u00a0mother can be exposed to the baby\u2019s Rh<sup>+<\/sup>\u00a0cells (<a class=\"autogenerated-content\" href=\"https:\/\/cnx.org\/contents\/FPtK1zmh@15.1:naelGNoN@9\/18-6-Blood-Typing#fig-ch19_06_01\">Figure 3<\/a>). Research has shown that this occurs in about 13\u221214 percent of such pregnancies. After exposure, the mother\u2019s immune system begins to generate anti-Rh antibodies. If the mother should then conceive another Rh<sup>+<\/sup>\u00a0baby, the Rh antibodies she has produced can cross the placenta into the fetal bloodstream and destroy the fetal RBCs. This condition, known as\u00a0<strong><span id=\"term2084\">hemolytic disease of the newborn (HDN)<\/span>\u00a0or erythroblastosis fetalis,<\/strong> may cause anemia in mild cases, but the agglutination and hemolysis can be so severe that without treatment the fetus may die in the womb or shortly after birth.<\/p>\r\n\r\n<div id=\"attachment_1707\" class=\"wp-caption aligncenter\">\r\n\r\n<a href=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/1094\/2016\/11\/10221542\/OSC_Microbio_19_01_HDN1.jpg\"><img class=\"wp-image-1707 size-large\" src=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/1094\/2016\/11\/10221542\/OSC_Microbio_19_01_HDN1-1024x538.jpg\" alt=\"a) First pregnancy with Rh+ fetus resulting in healthy newborn. The diagram shows an Rh- mother and an Rh+ fetus. Rh+ red blood cells cross the placenta into mother\u2019s circulation. This causes anti-Rh antibodies to be produced in the mother upon exposure to fetal Rh antigens. The second pregnancy with Rh+ fetus results in hemolytic newborn. The diagram shows an Rh- mother with an Rh+ fetus. Anti-Rh antibodies remain in mother\u2019s circulation from the first pregnancy and cross the placenta. Maternal anti-Rh antibodies attack and destroy fetal Rh+ red blood cells. B) First pregnancy with Rh+ fetus and anti-Rh antibody treatment resulting in healthy newborn The diagram shows an Rh- mother and an Rh+ fetus. Rh+ red blood cells fromt eh fetus clross placenta into mother\u2019s circulation. Anti-Rh antibodies (Rhogam) bind and inactivate fetal Rh antigens before they stimulate immune response in mother.\" width=\"1024\" height=\"538\" \/><\/a>\r\n<p class=\"wp-caption-text\"><strong>Figure 3:<\/strong> (a) When an Rh\u2212 mother has an Rh+ fetus, fetal erythrocytes are introduced into the mother\u2019s circulatory system before or during birth, leading to production of anti-Rh IgG antibodies. These antibodies remain in the mother and, if she becomes pregnant with a second Rh+ baby, they can cross the placenta and attach to fetal Rh+ erythrocytes. Complement-mediated hemolysis of fetal erythrocytes results in a lack of sufficient cells for proper oxygenation of the fetus. (b) HDN can be prevented by administering Rho(D) immune globulin during and after each pregnancy with an Rh+ fetus. The immune globulin binds fetal Rh+ RBCs that gain access to the mother\u2019s bloodstream, preventing activation of her primary immune response.<\/p>\r\n\r\n<\/div>\r\n<div class=\"os-figure\">\r\n<figure id=\"fig-ch19_06_01\"><span id=\"fs-id2502299\"><img id=\"96193\" src=\"https:\/\/cnx.org\/resources\/ce2a5857e2670efef399e9e2d04a4e2a0ce07ec3\" alt=\"This figure shows an umbilical artery and vein passing through the placenta on the top left. The top right panel shows the first exposure to Rh+ antibodies in the mother. The bottom right panel shows the response when the second exposure in the form of another fetus takes place. Textboxes detail the steps in each process.\" width=\"600\" \/><\/span><\/figure>\r\n<div class=\"os-caption-container\"><span class=\"os-title-label\"><strong>Figure 4:<\/strong>\u00a0\u00a0<\/span><span id=\"10711\" class=\"os-title\">Erythroblastosis Fetalis\u00a0<\/span><span class=\"os-caption\">The first exposure of an Rh<sup>\u2212<\/sup>\u00a0mother to Rh<sup>+<\/sup>\u00a0erythrocytes during pregnancy induces sensitization. Anti-Rh antibodies begin to circulate in the mother\u2019s bloodstream. A second exposure occurs with a subsequent pregnancy with an Rh<sup>+<\/sup>\u00a0fetus in the uterus. Maternal anti-Rh antibodies may cross the placenta and enter the fetal bloodstream, causing agglutination and hemolysis of fetal erythrocytes.<\/span><\/div>\r\n<\/div>\r\n<p id=\"fs-id2822281\">A drug known as<strong> RhoGAM,<\/strong> short for Rh immune globulin, can temporarily prevent the development of Rh antibodies in the Rh<sup>\u2212<\/sup>\u00a0mother, thereby averting this potentially serious disease for the fetus. RhoGAM antibodies destroy any fetal Rh<sup>+<\/sup>\u00a0erythrocytes that may cross the placental barrier. RhoGAM is normally administered to Rh<sup>\u2212<\/sup>\u00a0mothers during weeks 26\u221228 of pregnancy and within 72 hours following birth. It has proven remarkably effective in decreasing the incidence of HDN. Earlier we noted that the incidence of HDN in an Rh<sup>+<\/sup>subsequent pregnancy to an Rh<sup>\u2212<\/sup>\u00a0mother is about 13\u201314 percent without preventive treatment. Since the introduction of RhoGAM in 1968, the incidence has dropped to about 0.1 percent in the United States.<\/p>\r\n\r\n<\/section><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/section><footer class=\"footer\">\r\n<div>\r\n<div class=\"page-footer\"><\/div>\r\n<\/div>\r\n<\/footer>","rendered":"<section id=\"main-content\" class=\"main-content\">\n<div class=\"media-body\">\n<div id=\"content\">\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\">\n<p id=\"fs-id2316252\">Blood transfusions in humans were risky procedures until the discovery of the major human blood groups by Karl Landsteiner, an Austrian biologist and physician, in 1900. Until that point, physicians did not understand that death sometimes followed blood transfusions, when the type of donor blood infused into the patient was incompatible with the patient\u2019s own blood. Blood groups are determined by the presence or absence of specific marker molecules on the plasma membranes of erythrocytes. With their discovery, it became possible for the first time to match patient-donor blood types and prevent transfusion reactions and deaths.<\/p>\n<section id=\"fs-id2382783\">\n<h2>Antigens, Antibodies, and Transfusion Reactions<\/h2>\n<p id=\"fs-id2715080\">Antigens are substances that the body does not recognize as belonging to the \u201cself\u201d and that therefore trigger a defensive response from the leukocytes of the immune system. (Seek more content for additional information on immunity.) Here, we will focus on the role of immunity in blood transfusion reactions. With RBCs in particular, you may see the antigens referred to as isoantigens or agglutinogens (surface antigens) and the antibodies referred to as isoantibodies or agglutinins. In this chapter, we will use the more common terms <strong>antigens and antibodies.<\/strong><\/p>\n<p id=\"fs-id1952985\"><strong>Antigens<\/strong> are generally large proteins, but may include other classes of organic molecules, including carbohydrates, lipids, and nucleic acids seen on RBCs. Following an infusion of incompatible blood, erythrocytes with foreign antigens appear in the bloodstream and trigger an immune response. Proteins called antibodies (immunoglobulins), which are produced by certain B lymphocytes called plasma cells, attach to the antigens on the plasma membranes of the infused erythrocytes and cause them to adhere to one another.<\/p>\n<ul id=\"fs-id2396137\">\n<li>Because the arms of the Y-shaped antibodies attach randomly to more than one nonself erythrocyte surface, they form clumps of erythrocytes. This process is called\u00a0<span id=\"term2080\">agglutination<\/span>.<\/li>\n<li>The clumps of erythrocytes block small blood vessels throughout the body, depriving tissues of oxygen and nutrients.<\/li>\n<li>As the erythrocyte clumps are degraded, in a process called\u00a0<strong><span id=\"term2081\">hemolysis<\/span><\/strong>, their hemoglobin is released into the bloodstream. This hemoglobin travels to the kidneys, which are responsible for filtration of the blood. However, the load of hemoglobin released can easily overwhelm the kidney\u2019s capacity to clear it, and the patient can quickly develop kidney failure.<\/li>\n<\/ul>\n<p id=\"fs-id2653848\">More than 50 antigens have been identified on erythrocyte membranes, but the most significant in terms of their potential harm to patients are classified in <strong>two groups: the ABO blood group and the Rh blood group.<\/strong><\/p>\n<\/section>\n<section id=\"fs-id2111265\">\n<h3>1. The ABO Blood Group<\/h3>\n<p id=\"fs-id2454712\">Although the\u00a0<span id=\"term2082\">ABO blood group<\/span>\u00a0name consists of three letters, ABO blood typing designates the presence or absence of just two antigens, A and B. Both are glycoproteins. People whose erythrocytes have A antigens on their erythrocyte membrane surfaces are designated blood type A, and those whose erythrocytes have B antigens are blood type B. People can also have both A and B antigens on their erythrocytes, in which case they are blood type AB. People with neither A nor B antigens are designated blood type O. ABO blood types are genetically determined.<\/p>\n<\/section>\n<div class=\"os-figure\">\n<figure id=\"fig-ch19_06_03\">\n<div style=\"width: 617px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" id=\"74906\" class=\"\" src=\"https:\/\/cnx.org\/resources\/a9fa9181b953f0a6a9596420b0f714ad4a497b16\" alt=\"This table shows the different blood types, the antibodies in plasma, the antigens in the red blood cell, and the blood compatible blood types in an emergency.\" width=\"607\" height=\"466\" \/><\/p>\n<p class=\"wp-caption-text\"><strong>Table\u00a0 1:\u00a0<\/strong>ABO Blood Group\u00a0This chart summarizes the characteristics of the blood types in the ABO blood group. See the text for more on the concept of a universal donor or recipient.<\/p>\n<\/div>\n<\/figure>\n<\/div>\n<section id=\"fs-id2111265\">Normally the body must be exposed to a foreign antigen before an antibody can be produced. This is not the case for the ABO blood group. Individuals with type A blood\u2014without any prior exposure to incompatible blood\u2014have preformed antibodies to the B antigen circulating in their blood plasma. These antibodies, referred to as anti-B antibodies, will cause agglutination and hemolysis if they ever encounter erythrocytes with B antigens. Similarly, an individual with type B blood has pre-formed anti-A antibodies. Individuals with type AB blood, which has both antigens, do not have preformed antibodies to either of these. People with type O blood lack antigens A and B on their erythrocytes, but both anti-A and anti-B antibodies circulate in their blood plasma.<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<section id=\"main-content\" class=\"main-content\">\n<div class=\"media-body\">\n<div id=\"content\">\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\">\n<section id=\"fs-id2344330\">\n<h2>2. Rh Blood Groups &#8211; Rhesus Factor<\/h2>\n<p id=\"fs-id2492889\">The\u00a0<span id=\"term2083\">Rh blood group<\/span>\u00a0is classified according to the presence or absence of a second erythrocyte antigen identified as Rh. (It was first discovered in a type of primate known as a <em><strong><span style=\"text-decoration: underline\">rhesus<\/span> <span style=\"text-decoration: underline\">macaque<\/span><\/strong><\/em>, which is often used in research, because its blood is similar to that of humans.) Although dozens of Rh antigens have been identified, only one, designated D, is clinically important. Those who have the Rh D antigen present on their erythrocytes\u2014about 85 percent of Americans\u2014are described as <strong>Rh positive (Rh<sup>+<\/sup>)<\/strong> and those who lack it are <strong>Rh negative (Rh<sup>\u2212<\/sup>).<\/strong> Note that the Rh group is distinct from the ABO group, so any individual, no matter their ABO blood type, may have or lack this Rh antigen. When identifying a patient\u2019s blood type, the Rh group is designated by adding the word positive or negative to the ABO type. For example, A positive (A<sup>+<\/sup>) means ABO group A blood with the Rh antigen present, and AB negative (AB<sup>\u2212<\/sup>) means ABO group AB blood without the Rh antigen.<\/p>\n<p>Besides being a consideration for blood transfusion, parents who differ based on Rh status must be cautious to ensure that maternal antibodies do not destroy their child\u2019s red blood cells during fetal development, which can cause hemolytic anemia.<\/p>\n<p style=\"text-align: center\"><strong><a class=\"autogenerated-content\" href=\"https:\/\/cnx.org\/contents\/FPtK1zmh@15.1:naelGNoN@9\/18-6-Blood-Typing#tbl-ch19_02\">Table\u00a0<\/a>summarizes the distribution of the ABO and Rh blood types within the United States.<\/strong><\/p>\n<div class=\"os-table\">\n<table id=\"tbl-ch19_02\" summary=\"Table 18.2\">\n<thead>\n<tr>\n<th colspan=\"5\" scope=\"col\">Summary of ABO and Rh Blood Types within the United States<\/th>\n<\/tr>\n<tr>\n<th scope=\"col\">Blood Type<\/th>\n<th scope=\"col\">African-Americans<\/th>\n<th scope=\"col\">Asian-Americans<\/th>\n<th scope=\"col\">Caucasian-Americans<\/th>\n<th scope=\"col\">Latino\/Latina-Americans<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>A<sup>+<\/sup><\/td>\n<td>24<\/td>\n<td>27<\/td>\n<td>33<\/td>\n<td>29<\/td>\n<\/tr>\n<tr>\n<td>A<sup>\u2212<\/sup><\/td>\n<td>2<\/td>\n<td>0.5<\/td>\n<td>7<\/td>\n<td>2<\/td>\n<\/tr>\n<tr>\n<td>B<sup>+<\/sup><\/td>\n<td>18<\/td>\n<td>25<\/td>\n<td>9<\/td>\n<td>9<\/td>\n<\/tr>\n<tr>\n<td>B<sup>\u2212<\/sup><\/td>\n<td>1<\/td>\n<td>0.4<\/td>\n<td>2<\/td>\n<td>1<\/td>\n<\/tr>\n<tr>\n<td>AB<sup>+<\/sup><\/td>\n<td>4<\/td>\n<td>7<\/td>\n<td>3<\/td>\n<td>2<\/td>\n<\/tr>\n<tr>\n<td>AB<sup>\u2212<\/sup><\/td>\n<td>0.3<\/td>\n<td>0.1<\/td>\n<td>1<\/td>\n<td>0.2<\/td>\n<\/tr>\n<tr>\n<td>O<sup>+<\/sup><\/td>\n<td>47<\/td>\n<td>39<\/td>\n<td>37<\/td>\n<td>53<\/td>\n<\/tr>\n<tr>\n<td>O<sup>\u2212<\/sup><\/td>\n<td>4<\/td>\n<td>1<\/td>\n<td>8<\/td>\n<td>4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<section id=\"fs-id2801178\">\n<h2>Determining ABO Blood Types<\/h2>\n<p id=\"fs-id2696923\">Clinicians are able to determine a patient\u2019s blood type quickly and easily using commercially prepared antibodies. An unknown blood sample is allocated into separate wells. Into one well a small amount of anti-A antibody is added, and to another a small amount of anti-B antibody. If the antigen is present, the antibodies will cause visible agglutination of the cells. The blood should also be tested for Rh antibodies.<\/p>\n<div class=\"os-figure\">\n<figure id=\"fig-ch19_06_02\">\n<div style=\"width: 527px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" id=\"65452\" src=\"https:\/\/cnx.org\/resources\/387433ee24cad9d0a576c5bd5944c5a726901211\" alt=\"This figure shows three different red blood cells with different blood types.\" width=\"517\" height=\"210\" \/><\/p>\n<p class=\"wp-caption-text\"><strong>Figure 1:\u00a0<\/strong> Blood group testing.<\/p>\n<\/div>\n<\/figure>\n<div class=\"os-caption-container\"><strong><span id=\"4426\" class=\"os-title\">Cross Matching Blood Types :<\/span><\/strong><\/div>\n<div class=\"os-caption-container\"><span class=\"os-caption\">This sample of a commercially produced \u201cbedside\u201d card enables quick typing of both a recipient\u2019s and donor\u2019s blood before transfusion. The card contains three reaction sites or wells. One is coated with an anti-A antibody, one with an anti-B antibody, and one with an anti-D antibody (tests for the presence of Rh factor D). Mixing a drop of blood and saline into each well enables the blood to interact with a preparation of type-specific antibodies, also called anti-seras. Agglutination of RBCs in a given site indicates a positive identification of the blood antigens, in this case A and Rh antigens for blood type A<sup>+<\/sup>. For the purpose of transfusion, the donor\u2019s and recipient\u2019s blood types must match.<\/span><\/div>\n<div><\/div>\n<div class=\"os-caption-container\"><span style=\"color: #077fab;font-size: 1.15em;font-weight: 600;text-align: initial\">ABO Transfusion Protocols<\/span><\/div>\n<div><\/div>\n<div class=\"os-caption-container\"><span style=\"font-size: 1rem;text-align: initial\">To avoid transfusion reactions, it is best to transfuse only matching blood types; that is, a type B<\/span><sup style=\"text-align: initial\">+<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0recipient should ideally receive blood only from a type B<\/span><sup style=\"text-align: initial\">+<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0donor and so on. That said, in emergency situations, when acute hemorrhage threatens the patient\u2019s life, there may not be time for cross matching to identify blood type. In these cases, blood from a\u00a0<\/span><strong><span id=\"term2085\" style=\"font-size: 1rem;text-align: initial\">universal donor<\/span><span style=\"font-size: 1rem;text-align: initial\">\u2014an individual with type O<\/span><sup style=\"text-align: initial\">\u2212<\/sup><\/strong><span style=\"font-size: 1rem;text-align: initial\"><strong>\u00a0blood<\/strong>\u2014may be transfused. Recall that type O erythrocytes do not display A or B antigens. Thus, anti-A or anti-B antibodies that might be circulating in the patient\u2019s blood plasma will not encounter any erythrocyte surface antigens on the donated blood and therefore will not be provoked into a response. One problem with this designation of universal donor is if the O<\/span><sup style=\"text-align: initial\">\u2212<\/sup><span style=\"font-size: 1rem;text-align: initial\">\u00a0individual had prior exposure to Rh antigen, Rh antibodies may be present in the donated blood. Also, introducing type O blood into an individual with type A, B, or AB blood will nevertheless introduce antibodies against both A and B antigens, as these are always circulating in the type O blood plasma. This may cause problems for the recipient, but because the volume of blood transfused is much lower than the volume of the patient\u2019s own blood, the adverse effects of the relatively few infused plasma antibodies are typically limited. Rh factor also plays a role. If Rh<\/span><sup style=\"text-align: initial\">\u2212<\/sup><span style=\"font-size: 1rem;text-align: initial\">individuals receiving blood have had prior exposure to Rh antigen, antibodies for this antigen may be present in the blood and trigger agglutination to some degree. Although it is always preferable to cross match a patient\u2019s blood before transfusing, in a true life-threatening emergency situation, this is not always possible, and these procedures may be implemented.<\/span><\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<div id=\"content\">\n<div id=\"9da7a518-da0d-4e20-98e2-cf76482fc6f0\">\n<section id=\"fs-id1921655\">\n<div id=\"attachment_2727\" style=\"width: 477px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/2868\/2019\/04\/30115504\/blood-Compatiblity-Capture.png\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-2727\" class=\"wp-image-2727\" src=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/2868\/2019\/04\/30115504\/blood-Compatiblity-Capture.png\" alt=\"\" width=\"467\" height=\"453\" \/><\/a><\/p>\n<p id=\"caption-attachment-2727\" class=\"wp-caption-text\"><strong>Figure 2<\/strong>: Blood transfusion<\/p>\n<\/div>\n<p id=\"fs-id2449664\">A patient with <strong>blood type AB<sup>+<\/sup>\u00a0is known as the\u00a0<span id=\"term2086\">universal recipient<\/span>.<\/strong> This patient can theoretically receive any type of blood, because the patient\u2019s own blood\u2014having both A and B antigens on the erythrocyte surface\u2014does not produce anti-A or anti-B antibodies. In addition, an Rh<sup>+<\/sup>\u00a0patient can receive both Rh<sup>+<\/sup>\u00a0and Rh<sup>\u2212<\/sup>\u00a0blood. However, keep in mind that the donor\u2019s blood will contain circulating antibodies, again with possible negative implications.<\/p>\n<p id=\"fs-id2585008\">At the scene of multiple-vehicle accidents, military engagements, and natural or human-caused disasters, many victims may suffer simultaneously from acute hemorrhage, yet type O blood may not be immediately available. In these circumstances, medics may at least try to replace some of the volume of blood that has been lost. This is done by intravenous administration of a saline solution that provides fluids and electrolytes in proportions equivalent to those of normal blood plasma. Research is ongoing to develop a safe and effective artificial blood that would carry out the oxygen-carrying function of blood without the RBCs, enabling transfusions in the field without concern for incompatibility. These blood substitutes normally contain hemoglobin- as well as perfluorocarbon-based oxygen carriers.<\/p>\n<\/section>\n<section id=\"fs-id1921655\">\n<footer class=\"footer\">\n<div>\n<div class=\"page-footer\">\n<h2><\/h2>\n<h2>The Cross-Matching Process<\/h2>\n<p>Much of the routine work of a blood bank involves testing blood from both donors and recipients to ensure that every recipient is given blood that is compatible and is as safe as possible. Several laboratory tests allow cross-matching of compatible blood between donor and recipient. Patients should ideally receive their own blood or type-specific blood products to minimize the chance of a transfusion reaction. Risks can be further reduced by cross-matching blood, but this process isn\u2019t always performed if time is short and the need for transfusion has not been anticipated.<\/p>\n<p>Cross-matching involves mixing a sample of the recipient\u2019s serum with a sample of the donor\u2019s red blood cells and checking if the mixture agglutinates, or forms clumps. These clumps are the result of antibodies binding the red blood cells together. If agglutination is not obvious by direct vision, blood bank technicians check for agglutination with a microscope. If agglutination occurs, that particular donor\u2019s blood cannot be transfused to that particular recipient.<\/p>\n<p><span style=\"color: #077fab;font-size: 1.15em;font-weight: 600\">Potential Transfusion Complications<\/span><\/p>\n<\/div>\n<\/div>\n<\/footer>\n<p>If a patient receives blood during a transfusion that is not compatible with his or her blood type, severe problems can occur. Acute hemolytic transfusion reactions occur if donated blood cells are attacked by matching host antibodies. This can cause shock-like symptoms, such as fever, hypotension, and disseminated intravascular coagulation from immune system mediated endothelial damage. Transfusion reactions are also associated with acute renal failure. Lung injury is common as well, due to pulmonary edema from fluid overload if plasma volume becomes too high or neutrophil activation during a transfusion reaction. If the donated blood is contaminated with bacteria, it may induce septic shock in the patient.<\/p>\n<\/section>\n<h2 class=\"os-caption-container\"><strong><span id=\"term2084\">Hemolytic disease of the newborn (HDN)<\/span>\u00a0or erythroblastosis fetalis:<\/strong><\/h2>\n<section id=\"fs-id2344330\">\n<p id=\"fs-id1899114\">In contrast to the ABO group antibodies, which are preformed, antibodies to the Rh antigen are produced only in Rh<sup>\u2212<\/sup>\u00a0individuals after exposure to the antigen. This process, called sensitization, occurs following a transfusion with Rh-incompatible blood or, more commonly, with the birth of an Rh<sup>+<\/sup>\u00a0baby to an Rh<sup>\u2212<\/sup>\u00a0mother. Problems are rare in a first pregnancy, since the baby\u2019s Rh<sup>+<\/sup>\u00a0cells rarely cross the placenta (the organ of gas and nutrient exchange between the baby and the mother). However, during or immediately after birth, the Rh<sup>\u2212<\/sup>\u00a0mother can be exposed to the baby\u2019s Rh<sup>+<\/sup>\u00a0cells (<a class=\"autogenerated-content\" href=\"https:\/\/cnx.org\/contents\/FPtK1zmh@15.1:naelGNoN@9\/18-6-Blood-Typing#fig-ch19_06_01\">Figure 3<\/a>). Research has shown that this occurs in about 13\u221214 percent of such pregnancies. After exposure, the mother\u2019s immune system begins to generate anti-Rh antibodies. If the mother should then conceive another Rh<sup>+<\/sup>\u00a0baby, the Rh antibodies she has produced can cross the placenta into the fetal bloodstream and destroy the fetal RBCs. This condition, known as\u00a0<strong><span id=\"term2084\">hemolytic disease of the newborn (HDN)<\/span>\u00a0or erythroblastosis fetalis,<\/strong> may cause anemia in mild cases, but the agglutination and hemolysis can be so severe that without treatment the fetus may die in the womb or shortly after birth.<\/p>\n<div id=\"attachment_1707\" class=\"wp-caption aligncenter\">\n<p><a href=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/1094\/2016\/11\/10221542\/OSC_Microbio_19_01_HDN1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1707 size-large\" src=\"https:\/\/s3-us-west-2.amazonaws.com\/courses-images\/wp-content\/uploads\/sites\/1094\/2016\/11\/10221542\/OSC_Microbio_19_01_HDN1-1024x538.jpg\" alt=\"a) First pregnancy with Rh+ fetus resulting in healthy newborn. The diagram shows an Rh- mother and an Rh+ fetus. Rh+ red blood cells cross the placenta into mother\u2019s circulation. This causes anti-Rh antibodies to be produced in the mother upon exposure to fetal Rh antigens. The second pregnancy with Rh+ fetus results in hemolytic newborn. The diagram shows an Rh- mother with an Rh+ fetus. Anti-Rh antibodies remain in mother\u2019s circulation from the first pregnancy and cross the placenta. Maternal anti-Rh antibodies attack and destroy fetal Rh+ red blood cells. B) First pregnancy with Rh+ fetus and anti-Rh antibody treatment resulting in healthy newborn The diagram shows an Rh- mother and an Rh+ fetus. Rh+ red blood cells fromt eh fetus clross placenta into mother\u2019s circulation. Anti-Rh antibodies (Rhogam) bind and inactivate fetal Rh antigens before they stimulate immune response in mother.\" width=\"1024\" height=\"538\" \/><\/a><\/p>\n<p class=\"wp-caption-text\"><strong>Figure 3:<\/strong> (a) When an Rh\u2212 mother has an Rh+ fetus, fetal erythrocytes are introduced into the mother\u2019s circulatory system before or during birth, leading to production of anti-Rh IgG antibodies. These antibodies remain in the mother and, if she becomes pregnant with a second Rh+ baby, they can cross the placenta and attach to fetal Rh+ erythrocytes. Complement-mediated hemolysis of fetal erythrocytes results in a lack of sufficient cells for proper oxygenation of the fetus. (b) HDN can be prevented by administering Rho(D) immune globulin during and after each pregnancy with an Rh+ fetus. The immune globulin binds fetal Rh+ RBCs that gain access to the mother\u2019s bloodstream, preventing activation of her primary immune response.<\/p>\n<\/div>\n<div class=\"os-figure\">\n<figure id=\"fig-ch19_06_01\"><span id=\"fs-id2502299\"><img decoding=\"async\" id=\"96193\" src=\"https:\/\/cnx.org\/resources\/ce2a5857e2670efef399e9e2d04a4e2a0ce07ec3\" alt=\"This figure shows an umbilical artery and vein passing through the placenta on the top left. The top right panel shows the first exposure to Rh+ antibodies in the mother. The bottom right panel shows the response when the second exposure in the form of another fetus takes place. Textboxes detail the steps in each process.\" width=\"600\" \/><\/span><\/figure>\n<div class=\"os-caption-container\"><span class=\"os-title-label\"><strong>Figure 4:<\/strong>\u00a0\u00a0<\/span><span id=\"10711\" class=\"os-title\">Erythroblastosis Fetalis\u00a0<\/span><span class=\"os-caption\">The first exposure of an Rh<sup>\u2212<\/sup>\u00a0mother to Rh<sup>+<\/sup>\u00a0erythrocytes during pregnancy induces sensitization. Anti-Rh antibodies begin to circulate in the mother\u2019s bloodstream. A second exposure occurs with a subsequent pregnancy with an Rh<sup>+<\/sup>\u00a0fetus in the uterus. Maternal anti-Rh antibodies may cross the placenta and enter the fetal bloodstream, causing agglutination and hemolysis of fetal erythrocytes.<\/span><\/div>\n<\/div>\n<p id=\"fs-id2822281\">A drug known as<strong> RhoGAM,<\/strong> short for Rh immune globulin, can temporarily prevent the development of Rh antibodies in the Rh<sup>\u2212<\/sup>\u00a0mother, thereby averting this potentially serious disease for the fetus. RhoGAM antibodies destroy any fetal Rh<sup>+<\/sup>\u00a0erythrocytes that may cross the placental barrier. RhoGAM is normally administered to Rh<sup>\u2212<\/sup>\u00a0mothers during weeks 26\u221228 of pregnancy and within 72 hours following birth. It has proven remarkably effective in decreasing the incidence of HDN. Earlier we noted that the incidence of HDN in an Rh<sup>+<\/sup>subsequent pregnancy to an Rh<sup>\u2212<\/sup>\u00a0mother is about 13\u201314 percent without preventive treatment. Since the introduction of RhoGAM in 1968, the incidence has dropped to about 0.1 percent in the United States.<\/p>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<footer class=\"footer\">\n<div>\n<div class=\"page-footer\"><\/div>\n<\/div>\n<\/footer>\n","protected":false},"author":141992,"menu_order":6,"template":"","meta":{"_candela_citation":"[]","CANDELA_OUTCOMES_GUID":"","pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[],"contributor":[],"license":[],"class_list":["post-4888","chapter","type-chapter","status-publish","hentry"],"part":4882,"_links":{"self":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapters\/4888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/wp\/v2\/users\/141992"}],"version-history":[{"count":7,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapters\/4888\/revisions"}],"predecessor-version":[{"id":6194,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapters\/4888\/revisions\/6194"}],"part":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/parts\/4882"}],"metadata":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapters\/4888\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/wp\/v2\/media?parent=4888"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/pressbooks\/v2\/chapter-type?post=4888"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/wp\/v2\/contributor?post=4888"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/courses.lumenlearning.com\/suny-dutchess-ap1\/wp-json\/wp\/v2\/license?post=4888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}